[1]刘洋 卢琳 龚凤英 朱惠娟 潘慧.糖皮质激素受体基因及其变异在库欣综合征中的作用[J].国际内分泌代谢杂志,2018,38(02):135-138.[doi:10.3760/cma.j.issn.1673-4157.2018.02.017]
　Liu Yang,Lu Lin,Gong Fengying,et al.Role of glucocorticoid receptor and related gene mutation in Cushing's syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(02):135-138.[doi:10.3760/cma.j.issn.1673-4157.2018.02.017]
点击复制

糖皮质激素受体基因及其变异在库欣综合征中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年02期
页码:
135-138
栏目:
基础研究
出版日期:
2018-03-20

文章信息/Info

Title:
Role of glucocorticoid receptor and related gene mutation in Cushing's syndrome
作者:
刘洋 卢琳 龚凤英 朱惠娟 潘慧
100730 北京,中国医学科学院北京协和医学院北京协和医院内分泌科,国家卫生和计划生育委员会内分泌重点实验室
Author(s):
Liu Yang;  Lu Lin;  Gong Fengying;  Zhu Huijuan;  Pan Hui
Key Laboratory of Endocrinology, National Health and Family Planning Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College,Beijing 100730, China
关键词:
糖皮质激素受体;  库欣综合征;  垂体ACTH腺瘤;  治疗
Keywords:
Glucocorticoid receptor;  Cushing's syndrome;  Pituitary ACTH adenoma;  Management
DOI:
10.3760/cma.j.issn.1673-4157.2018.02.017
摘要:
库欣综合征是由于各种原因所致的皮质醇异常分泌增多,引起高皮质醇血症、代谢紊乱的临床综合征,糖皮质激素受体(GR)是皮质醇结合靶点。GR的表达量、基因变异及其通路中多个因子(热休克蛋白、11β羟基类固醇羟化酶、芳烃受体作用蛋白、睾丸孤核受体4和Brg1蛋白)在库欣综合征及相关并发症的发病机制中发挥重要作用。作用于GR及相关通路的药物包括GR拮抗剂米非司酮、热休克蛋白抑制剂和11β羟基类固醇羟化酶抑制剂等对库欣综合征的治疗具有重大意义。
Abstract:
Cushing's syndrome is a collection of metabolic disturbance caused by hypercortisolism due to various mechanisms. Cortisol acts through glucocorticoid receptor(GR). The expression and gene mutation of GR, as well as several molecules in its signal pathway,including hot-shock protein(HSP), 11β-hydroxyl steroid hydroxylase(11β-HSD), aryl hydrocarbon receptor interacting protein, testicular orphan receptor 4 and Brg1, play important roles in the pathogenesis of Cushing's syndrome and related complications. Medications targeting GR and related pathways for treating Cushing's syndrome, including GR antagonist mifepristone, HSP inhibitor silibinin and 11β-HSD inhibitors, have demonstrated great clinical potentials.

参考文献/References:


[1] Hollenberg SM,Weinberger C,Ong ES,et al.Primary structure and expression of a functional human glucocorticoid receptor cDNA[J].Nature,1985,318(6047):635-641.
[2] Schaaf MJ,Cidlowski JA.Molecular mechanisms of glucocorticoid action and resistance[J].J Steroid Biochem Mol Biol,2002,83(1-5):37-48.
[3] Kirschke E,Goswami D,Southworth D,et al.Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70chaperone cycles[J].Cell,2014,157(7):1685-1697.DOI:10.1016/j.cell.2014.04.038.
[4] Dostert A,Heinzel T.Negative glucocorticoid receptor response elements and their role in glucocorticoid action[J].Curr Pharm Des,2004,10(23):2807-2816.
[5] Huizenga NA,de Lange P,Koper JW,et al. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus[J].J Clin Endocrinol Metab,1998,83(3):917-921.DOI:10.1210/jcem.83.3.4648.
[6] Mu YM,Takayanagi R,Imasaki K,et al. Low level of glucocorticoid receptor messenger ribonucleic acid in pituitary adenomas manifesting Cushing's disease with resistance to a high dose-dexamethasone suppression test[J].Clin Endocrinol(Oxf),1998,49(3):301-306.DOI:10.1046/j.1365-2265.1998.00520.x.
[7] Dahia PL,Honegger J,Reincke M,et al.Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors[J].J Clin Endocrinol Metab,1997,82(4):1088-1093.DOI:10.1210/jcem.82.4.3861.
[8] Tacon LJ,Soon PS,Gill AJ,et al.The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors[J].J Clin Endocrinol Metab,2009,94(11):4591-4599.DOI:10.1210/jc.2009-0546.
[9] Bouligand J,Delemer B,Hecart AC,et al. Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess[J].PLoS One,2010,5(10):e13563.DOI:10.1371/journal.pone.0013563.
[10] Zhu HJ,Dai YF,Wang O,et al.Generalized glucocorticoid resistance accompanied with an adrenocortical adenoma and caused by a novel point mutation of human glucocorticoid receptor gene[J].Chin Med J(Engl),2011,124(4):551-555.
[11] Song ZJ,Reitman ZJ,Ma ZY,et al.The genome-wide mutational landscape of pituitary adenomas[J].Cell Res,2016,26(11):1255-1259.DOI:10.1038/cr.2016.114.
[12] Vitellius G,Fagart J,Delemer B,et al.Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance[J].Hum Mutat,2016,37(8):794-803.DOI:10.1002/humu.23008.
[13] Charmandari E,Kino T,Ichijo T,et al. A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance[J].J Clin Endocrinol Metab,2007,92(10):3986-3990.DOI:10.1210/jc.2006-2830.
[14] Riebold M,Kozany C,Freiburger L,et al.A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease[J].Nat Med,2015,21(3):276-280.DOI:10.1038/nm.3776.
[15] Morgan SA,Hassan-Smith ZK,Lavery GG.Mechanisms in endocrinology: tissue-specific activation of cortisol in Cushing's syndrome[J].Eur J Endocrinol,2016,175(2):R83-R89.DOI:10.1530/EJE-15-1237.
[16] Morgan SA,McCabe EL,Gathercole LL,et al.11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess[J].Proc Natl Acad Sci U S A,2014,111(24):E2482-E2491.DOI:10.1073/pnas.1323681111.
[17] Korbonits M,Bujalska I,Shimojo M,et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors[J].J Clin Endocrinol Metab,2001,86(6):2728-2733.DOI:10.1210/jcem.86.6.7563.
[18] Tahir A,Chahal HS,Korbonits M.Molecular genetics of the aip gene in familial pituitary tumorigenesis[J].Prog Brain Res,2010,182:229-253.DOI:10.1016/S0079-6123(10)82010-2.
[19] Daly AF,Vanbellinghen JF,Khoo SK,et al.Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families[J].J Clin Endocrinol Metab,2007,92(5):1891-1896.DOI:10.1210/jc.2006-2513.
[20] Scudder CJ,Niessen SJ,Catchpole B,et al.Feline hypersomatotropism and acromegaly tumorigenesis: a potential role for the AIP gene[J].Domest Anim Endocrinol,2017,59:134-139.DOI:10.1016/j.domaniend.2016.11.005.
[21] Stratakis CA,Tichomirowa MA,Boikos S,et al.The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes[J].Clin Genet,2010,78(5):457-463.DOI:10.1111/j.1399-0004.2010.01406.x.
[22] Zhang D,Du L,Heaney AP.Testicular receptor-4: novel regulator of glucocorticoid resistance[J].J Clin Endocrinol Metab,2016,101(8):3123-3133.DOI:10.1210/jc.2016-1379.
[23] Bilodeau S,Vallette-Kasic S,Gauthier Y,et al.Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease[J].Genes Dev,2006,20(20):2871-2886.DOI:10.1101/gad.1444606.
[24] Trementino L,Appolloni G,Concettoni C,et al.Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome[J].Eur J Endocrinol,2012,166(1):35-42. DOI:10.1530/EJE-11-0722.
[25] van Schoor NM,Dennison E,Lips P,et al.Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor[J].Clin Endocrinol(Oxf),2007,67(6):871-878.DOI:10.1111/j.1365-2265.2007.02978.x.
[26] Moreira RP,Bachega TA,Machado MC,et al.Modulatory effect of Bcl Ⅰ GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's disease[J].Clinics(Sao Paulo),2013,68(5):579-585.DOI:10.6061/clinics/2013(05)01.
[27] Trementino L,Appolloni G,Ceccoli L,et al.Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants[J].Osteoporos Int,2014,25(3):913-921.DOI:10.1007/s00198-013-2520-5.
[28] Andela CD,van Haalen FM,Ragnarsson O,et al. Mechanisms in endocrinology: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies[J].Eur J Endocrinol,2015,173(1):R1-R14. DOI:10.1530/EJE-14-1101.
[29] 杨晨蝶, 幸兵. 库欣综合征所致精神症状的机制[J]. 基础医学与临床, 2014, 34(10): 1438-1441.DOI:10.3969/j.issn.1001-6325.2014.10.031.
[30] Castinetti F,Conte-Devolx B,Brue T.Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone[J].Neuroendocrinology,2010,92(Suppl 1):125-130.DOI:10.1159/000314224.
[31] Gibbs JP,Emery MG,McCaffery I,et al.Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1)activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor[J].J Clin Pharmacol,2011,51(6):830-841.DOI:10.1177/0091270010374470.

相似文献/References:

[1]高玉婷,杜琴,刘丽翼,等.氟康唑治疗库欣综合征的临床运用初探[J].国际内分泌代谢杂志,2021,41(02):91.[doi:10.3760/cma.j.cn121383-20200624-06054]
　Gao Yuting,Du Qin,Liu Liyi,et al.Primary reports about clinical application of fluconazole in Cushing's syndrome[J].International Journal of Endocrinology and Metabolism,2021,41(02):91.[doi:10.3760/cma.j.cn121383-20200624-06054]

备注/Memo

备注/Memo:
基金项目:中华医学会临床医学科研专项资金-下丘脑垂体研究项目(13050940479); 国家临床重点专科基金(WBYZ2011-873); 中国医学科学院医学与健康科技创新工程项目(CAMS-2017-I2M-1-011)
通信作者:卢琳,Email:lulin88@sina.com
更新日期/Last Update: 1900-01-01